Wider Access Promised
The introduction of multiple generic semaglutide brands in India marks a significant development, expected to drastically reduce the drug's cost and, consequently,
improve accessibility for a larger patient population. Previously, the innovator drug's high price point limited its use for many struggling with chronic conditions such as diabetes, obesity, and non-alcoholic fatty liver disease. With generic versions anticipated to cost as little as Rs 1,296 per month for the lowest dosage, individuals who were previously excluded from treatment options due to financial constraints may now find relief. This cost-effectiveness is particularly crucial in a country like India, often dubbed the 'pharmacy of the world,' known for its expertise in producing affordable generic medications for global markets. Experts anticipate that this influx of cost-effective options will not only benefit patients within India but also pave the way for wider availability across Asia and Africa, leveraging India's established generic manufacturing prowess. The potential for these medications to alleviate the burden of chronic diseases is immense, opening doors to better health outcomes for many.
Quality and Cold Chain Concerns
Despite the celebratory mood surrounding increased affordability, leading diabetologists have voiced significant concerns regarding the quality and handling of these newly launched generic semaglutide products. With nearly 50 brands entering the market simultaneously, each potentially utilizing different manufacturing processes, there is an inherent risk of variations in drug purity and efficacy. Specialists emphasize the importance of selecting generics from manufacturers with a proven track record of producing high-quality medications to minimize the potential for impurities and adverse side effects. Furthermore, semaglutide, being an injectable medication, requires strict temperature control throughout its supply chain – a 'cold chain' – to maintain its potency. Many of the new generic manufacturers may lack the established infrastructure and experience necessary for the reliable transport and storage of temperature-sensitive injectables, posing a risk to drug integrity. Proper home storage, akin to insulin, by keeping it in the refrigerator door, is also a critical instruction that needs to be adhered to by patients.
Cautious Prescribing Advised
The widespread availability of generic semaglutide has prompted diabetologists to issue strong advisories against its misuse and overuse. These potent medications, which impact both the brain and the digestive system to regulate blood sugar and appetite, are not intended for casual weight loss or for individuals without a clear medical need. While side effects are often mild, potential serious risks include pancreatitis, thyroid cancer, gastroparesis (paralysis of the stomach), and vision impairment. There are growing reports of semaglutide being prescribed by non-physicians, such as gym instructors and dieticians, which is a practice experts strongly condemn. The use of semaglutide must be strictly confined to qualified physicians, particularly endocrinologists, and dispensed only with a valid prescription. It should not be accessible over-the-counter or through unregulated online pharmacies to prevent inappropriate usage and potential harm. A holistic approach involving lifestyle modifications, including diet and exercise, remains paramount for sustainable health outcomes.
